Evidence map›Paper›PMID 37692949›Full record

ArticleAmerican journal of translational research2023

Raloxifene, a SERM targets PD-L1: an in-silico study.

Chirag Chopra, Tenzen Yodun, Harpreet Singh, Bhupender Singh, Shashank K Singh, Umesh Goutam

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chirag ChopraSchool of Bioengineering and Biosciences, Lovely Professional University Phagwara, Punjab, India.
Tenzen YodunCancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR) Jammu, J&K, India.
Harpreet SinghDepartment of Bioinformatics, Hans Raj Mahila Maha Vidyalaya Jalandhar, Punjab, India.
Bhupender SinghSchool of Bioengineering and Biosciences, Lovely Professional University Phagwara, Punjab, India.
Shashank K SinghCancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR) Jammu, J&K, India.
Umesh GoutamSchool of Bioengineering and Biosciences, Lovely Professional University Phagwara, Punjab, India.
Lovely Professional University · INIndian Institute of Integrative Medicine · INHans Raj Mahila Maha Vidyalaya · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesImmunotherapeutic interventions in cancer have been considerably successful and widely accepted for cancer treatment, but are costly and cannot be afforded by all patients. Because of the high cost, the pharmaceutical research groups across the world are sufficiently motivated to discover or design small molecule inhibitors to treat cancer through inhibition of the immune checkpoint proteins previously targeted with monoclonal antibodies. The presented study was designed with an aim to establish raloxifene, a selective estrogen receptor modulator (SERM) as a potential ligand of the immune checkpoint protein Programmed death ligand-1 (PD-L1).

methodsIn the presented study, the

resultsThe

conclusionsPD-L1 is a potential target of the SERM raloxifene in-silico. Overall, this study is one step further towards immune checkpoint blockade using small-molecule inhibitors.

Indexed as

ADMEanticancerautodockimmune checkpointin-silicoPD-L1raloxifeneVina

Identifiers

PMID37692949
PMCPMC10492081
OpenAlexW4386592937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.